Soleil Boughton Sells 6,236 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Posted by George Bondi on Sep 19th, 2026

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Soleil Boughton sold 6,236 shares of the business’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $27.86, for a total transaction of $173,734.96. Following the completion of the sale, the insider owned 304,270 shares in the company, valued at approximately $8,476,962.20. This trade represents a 2.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.33, for a total transaction of $97,965.14.
On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Stock Up 0.4%

NYSE HIMS opened at $28.00 on Friday. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The company’s 50 day simple moving average is $30.06 and its 200 day simple moving average is $27.60. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $65.30. The company has a market capitalization of $6.53 billion, a P/E ratio of -44.45 and a beta of 2.42.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company’s quarterly revenue was up 38.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.17 earnings per share. Equities research analysts expect that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bienville Capital Management LLC acquired a new position in Hims & Hers Health in the 2nd quarter valued at approximately $27,242,000. Engineers Gate Manager LP acquired a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $232,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Hims & Hers Health during the 2nd quarter valued at $147,000. Baird Financial Group Inc. grew its holdings in shares of Hims & Hers Health by 384.6% during the 2nd quarter. Baird Financial Group Inc. now owns 65,575 shares of the company’s stock valued at $2,273,000 after acquiring an additional 52,043 shares in the last quarter. Finally, Nykredit A S acquired a new position in shares of Hims & Hers Health in the second quarter worth $222,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

Neutral Sentiment: CFO Oluyemi Okupe sold 12,313 shares worth approximately $355,000, reducing his position by 4.66%. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, making it a weaker standalone bearish signal. CFO SEC filing
Neutral Sentiment: COO Michael Chi sold 14,027 shares for about $398,000, while insider Soleil Boughton sold 6,236 shares for approximately $174,000. Both sales were made through pre-arranged Rule 10b5-1 plans; however, the cluster of insider sales may still reinforce investor caution. Insider SEC filing
Negative Sentiment: Multiple law firms announced or promoted a securities class action against HIMS involving investors who purchased shares between August 4, 2025, and July 29, 2026. The deadline to seek lead-plaintiff status is November 2, 2026, increasing headline and litigation risk. Securities class action report
Negative Sentiment: The lawsuits stem from allegations related to the FTC’s complaint, including potential misstatements or omissions concerning Hims & Hers’ privacy, data-sharing, billing and business practices. The allegations remain unproven, but could lead to legal costs, regulatory consequences and reputational damage. HIMS lawsuit allegations

Analyst Ratings Changes

A number of equities analysts recently issued reports on HIMS shares. Morgan Stanley lifted their target price on Hims & Hers Health from $21.00 to $28.00 and gave the stock an “equal weight” rating in a report on Tuesday, August 11th. Needham & Company LLC increased their price target on Hims & Hers Health from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Wall Street Zen raised Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. TD Cowen boosted their price objective on Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Finally, Citigroup reduced their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $32.43.

Read Our Latest Stock Report on HIMS

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.